Europe’s medical devices industry sees a drop of 4.7% in deal activity in Q2 2020

24 July 2020 (Last Updated July 24th, 2020 13:31)

Europe’s medical devices industry sees a drop of 4.7% in deal activity in Q2 2020

Europe’s medical devices industry saw a drop of 4.7% in overall deal activity during Q2 2020, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 82 deals worth $971.42m were announced for the region during Q2 2020, against the last four-quarter average of 86 deals.

Of all the deal types, venture financing saw most activity in Q2 2020 with 48, representing a 58.5% share for the region.

In second place was M&A with 23 deals, followed by private equity deals with 11 transactions, respectively capturing a 28.05% and 13.4% share of the overall deal activity for the quarter.

In terms of value of deals, private equity was the leading category in Europe’s medical devices industry with $562.77m, while venture financing and M&A deals totalled $375m and $33.65m, respectively.

Europe medical devices industry deals in Q2 2020: Top deals

The top five medical devices deals accounted for 62.6% of the overall value during Q2 2020.

The combined value of the top five medical devices deals stood at $608.22m, against the overall value of $971.42m recorded for the quarter.

The top five medical devices industry deals of Q2 2020 tracked by GlobalData were:

1) The Blackstone Group’s $337m private equity deal with Medtronic

2) The $135.89m private equity deal with Abcam by Durable Capital Partners

3) EGS Beteiligungen’s $51.97m venture financing of Spineart Geneva

4) The $43.35m venture financing of Robocath by Anaxago, MicroPort Scientific, Tus-Holdings and Zhejiang Silk Road Fund

5) Decheng Capital, Earlybird Venture Capital GmbH & Co, Endeavour Vision, Innovation Development Oman Holding SAOC, Longitude Capital Management Co and Wellington Partners Venture Capital’s venture financing of Polares Medical for $40m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.